# US 8,518,915 B2 · Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,518,915 B2
- Document ID: US8518915B2
- Status: Granted
- Kind: B2
- Application number: 12/667,061
- Filed: 2007-06-29
- Published: 2011-03-03
- Granted: 2013-08-27
- Earliest claimed: 2007-06-29
- Assignees: Mitotech SA
- Applicants: Maxim Vladimirovich Skulachev; Vladimir Petrovich Skulachev
- Inventors: Maxim Vladimirovich Skulachev; Vladimir Petrovich Skulachev
- Web page: https://patentgrep.com/patent/US8518915B2

## CPC

- A61K 31/66: Phosphorus compounds
- A61K 47/54: the modifying agent being an organic compound
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 39/06: Free radical scavengers or antioxidants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to pharmacology and medicine, in particular to a class of mitochondrially-addressed compounds which can be used in the pharmaceutical compositions of medicinal agents (preparations) for preventing and treating cardiovascular diseases and diseases and pathological conditions caused by disturbed blood circulation or oxygen supply to tissues and organs.

## Claims

### Claim 1

A pharmaceutical formulation comprising a compound which is SkQR1:
and its reduced form SkQR1H2:
wherein Z− is a pharmacologically acceptable anion.

### Claim 2

A method for decreasing the likelihood of developing damage to heart, brain, and/or kidney caused by ischemia and/or stroke, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a compound of Formula I:
wherein:
A is the effector moiety—antioxidant:
and/or reduced form thereof, wherein:
m is an integer from 1 to 3; and
each Y is methyl;
L is a linker group, comprising:
a) a straight or branched hydrocarbon chain which can be optionally substituted by one or more substituents and optionally contains one or more double or triple bonds; or
b) a natural isoprene chain;
n is an integer from 1 to 20; and
B is a targeting group, comprising Sk+Z−, wherein:
Sk+ is a lipophilic cation; and
Z− is a pharmacologically acceptable anion; and
a pharmaceutically acceptable carrier thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the composition administered is a plastoquinone of structure:
wherein m=2.

### Claim 4 (depends on 2)

The method of claim 2, wherein the compound of Formula I is SkQ1:
where Z− is a pharmacologically acceptable anion.

### Claim 5 (depends on 2)

The method of claim 2, wherein the compound of Formula I is SkQR1:
where Z− is a pharmacologically acceptable anion.